Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection

Table 2 Univariate and multivariate analysis of factors associated with recurrence

	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Gender
Male	1
Female	0.882 (0.64-1.21)	0.443
Age (yr)	0.997 (0.98-1.01)	0.758
HBV
No	1
Yes	1.079 (0.78-1.49)	0.641
HCV
No	1
Yes	1.373 (0.92-2.05)	0.12
Platelet × 103	1.002 (0.98-1.02)	0.775
Tumor size (cm)	1.058 (1.02-1.10)	0.003	1.040 (0.99-1.08)	0.059
No. of tumor
Single	1		1
Multiple	1.793 (1.26-2.54)	0.001	1.646 (1.15-2.35)	0.006
mVI
No	1		1
Yes	1.889 (1.30-2.73)	0.001	1.573 (1.05-2.35)	0.026
Stage
Stage I	1
Stage II or higher	1.535 (1.10-2.12)	0.01
Resection margin
Free margin	1
Positive margin	1.359 (0.69-2.67)	0.375
Anti-viral treatment
No	1
Yes	0.935 (0.68-1.28)	0.682
AFP
Normal group	1		1
Response group	1.137 (0.80-1.59)	0.458	1.067 (0.75-1.50)	0.711
Non-response group	2.438 (1.45-4.08)	0.001	2.425 (1.42-4.13)	0.001

AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; HCV: Hepatitis C virus.